Effect of the Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccine on the Risk of Rejection in Solid Organ Transplant Recipients in England: a Self-controlled Case Series

Overview

Journal BMJ Open

Specialty General Medicine

Date 2016 Jan 30

PMID 26823177

Citations 9

Authors

Catherine Cohet

Francois Haguinet

Gael Dos Santos

Dave Webb

John Logie

Germano Lc Ferreira

Dominique Rosillon

Vivek Shinde

Affiliations

Soon will be listed here.

Abstract

Objective: To assess the risk of solid organ transplant (SOT) rejection after vaccination with the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine Pandemrix.

Design: Self-controlled case series (SCCS) in the UK Clinical Practice Research Datalink (CPRD) and its linked component of the Hospital Episodes Statistics (HES) inpatient database. Analyses were conducted using the SCCS method for censored, perturbed or curtailed post-event exposure.

Participants: Of the 184 transplant recipients having experienced at least one SOT rejection (liver, kidney, lung, heart or pancreas) during the study period from 1 October 2009 to 31 October 2010, 91 participants were included in the main analysis, of which 71 had been exposed to Pandemrix.

Main Outcome Measures: Occurrence of SOT rejection during risk (30 and 60 days after any Pandemrix dose) and control periods. Covariates in the CPRD included time since transplantation, seasonal influenza vaccination, bacterial and viral infections, previous SOT rejections and malignancies.

Results: The relative incidence (RI) of rejection of any one of the five transplanted organs, adjusted for time since transplantation, was 1.05 (95% CI 0.52 to 2.14) and 0.80 (95% CI 0.42 to 1.50) within 30 and 60 days after vaccination, respectively. Similar estimates were observed for rejection of a kidney only, the most commonly transplanted organ (RI within 30 days after vaccination: 0.85 (95% CI 0.38 to 1.90)). Across various models and sensitivity analyses, RI estimates remained stable and within a consistent range around 1.0.

Conclusions: These results suggest a reassuring safety profile for Pandemrix with regard to the risk of rejection in SOT recipients in England and contribute to inform the benefit-risk of AS03-adjuvanted pandemic influenza vaccines in transplanted patients in the event of future pandemics.

Trial Registration Number: NCT01715792.

Citing Articles

Safety and Efficacy of Influenza Vaccination in Kidney Graft Recipients in Late Period After Kidney Transplantation.

Zawiasa-Bryszewska A, Nowicka M, Gorska M, Edyko P, Edyko K, Tworek D Vaccines (Basel). 2025; 13(2).

PMID: 40006735 PMC: 11861709. DOI: 10.3390/vaccines13020189.

Tree-temporal scan statistics for safety signal detection in vaccine clinical trials.

Haguinet F, Tibaldi F, Dessart C, Bate A Pharm Stat. 2024; 23(6):813-836.

PMID: 38622834 PMC: 11602958. DOI: 10.1002/pst.2391.

Transplantation programs facing lack of empirical evidence on SARS-CoV-2 vaccination: A society recommendation consensus update.

Nevermann N, Wiering L, Wu H, Moroder P, Brandl A, Globke B Transpl Infect Dis. 2021; 23(4):e13696.

PMID: 34288294 PMC: 8420432. DOI: 10.1111/tid.13696.

All-Cause Hospitalizations after Large-Scale Hurricanes among Older Adults: A Self-Controlled Case Series Study.

Bell S, Iwashyna T, Zhang X, Chen B, Davis M Prehosp Disaster Med. 2020; 36(1):25-31.

PMID: 33198843 PMC: 7853425. DOI: 10.1017/S1049023X20001387.

Effect of Influenza Vaccination Inducing Antibody Mediated Rejection in Solid Organ Transplant Recipients.

Cordero E, Bulnes-Ramos A, Aguilar-Guisado M, Gonzalez Escribano F, Olivas I, Torre-Cisneros J Front Immunol. 2020; 11:1917.

PMID: 33123119 PMC: 7574595. DOI: 10.3389/fimmu.2020.01917.

References

Siegrist C, Ambrosioni J, Bel M, Combescure C, Hadaya K, Martin P . Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. Antivir Ther. 2012; 17(5):893-903. DOI: 10.3851/IMP2103. View

Crawford N, Cheng A, Andrews N, Charles P, Clothier H, Day B . Guillain-Barré syndrome following pandemic (H1N1) 2009 influenza A immunisation in Victoria: a self-controlled case series. Med J Aust. 2012; 197(10):574-8. DOI: 10.5694/mja12.10534. View

Danziger-Isakov L, Cherkassky L, Siegel H, McManamon M, Kramer K, Budev M . Effects of influenza immunization on humoral and cellular alloreactivity in humans. Transplantation. 2010; 89(7):838-44. PMC: 3590069. DOI: 10.1097/TP.0b013e3181ca56f8. View

Broeders N, Hombrouck A, Lemy A, Wissing K, Racape J, Gastaldello K . Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. Clin J Am Soc Nephrol. 2011; 6(11):2573-8. PMC: 3359578. DOI: 10.2215/CJN.04670511. View

Kumar D, Blumberg E, Danziger-Isakov L, Kotton C, Halasa N, Ison M . Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant. 2011; 11(10):2020-30. DOI: 10.1111/j.1600-6143.2011.03753.x. View

Scharpe J, Evenepoel P, Maes B, Bammens B, Claes K, Osterhaus A . Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant. 2007; 8(2):332-7. DOI: 10.1111/j.1600-6143.2007.02066.x. View

Lawal A, Basler C, Branch A, Gutierrez J, Schwartz M, Schiano T . Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant. 2004; 4(11):1805-9. DOI: 10.1111/j.1600-6143.2004.00564.x. View

Kumar D, Michaels M, Morris M, Green M, Avery R, Liu C . Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010; 10(8):521-6. PMC: 3045703. DOI: 10.1016/S1473-3099(10)70133-X. View

Schuurmans M, Tini G, Dalar L, Fretz G, Benden C, Boehler A . Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: coverage, safety and clinical effectiveness in the Zurich cohort. J Heart Lung Transplant. 2011; 30(6):685-90. DOI: 10.1016/j.healun.2011.01.707. View

10.

Arnheim-Dahlstrom L, Hallgren J, Weibull C, Sparen P . Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study. BMJ. 2013; 345:e7594. PMC: 3532724. DOI: 10.1136/bmj.e7594. View

11.

Romio S, Weibel D, Dieleman J, Olberg H, de Vries C, Sammon C . Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe. PLoS One. 2014; 9(1):e82222. PMC: 3880265. DOI: 10.1371/journal.pone.0082222. View

12.

Sinha S, Peach G, Poloniecki J, Thompson M, Holt P . Studies using English administrative data (Hospital Episode Statistics) to assess health-care outcomes--systematic review and recommendations for reporting. Eur J Public Health. 2012; 23(1):86-92. DOI: 10.1093/eurpub/cks046. View

13.

Torii Y, Kimura H, Ochi N, Kaneko K, Ando H, Kiuchi T . Immunogenicity of inactivated 2009 H1N1 influenza vaccine in pediatric liver transplant recipients. Vaccine. 2011; 29(25):4187-9. DOI: 10.1016/j.vaccine.2011.04.012. View

14.

Low C, Kee T, Chan K, Oon L, Tan C, Tee N . Pandemic (H1N1) 2009 infection in adult solid organ transplant recipients in Singapore. Transplantation. 2010; 90(9):1016-21. DOI: 10.1097/TP.0b013e3181f546cf. View

15.

Hardelid P, Fleming D, McMenamin J, Andrews N, Robertson C, Sebastianpillai P . Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009-2010. Euro Surveill. 2011; 16(2). View

16.

Magnani G, Falchetti E, Pollini G, Reggiani L, Grigioni F, Coccolo F . Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J Heart Lung Transplant. 2005; 24(5):588-92. DOI: 10.1016/j.healun.2004.03.004. View

17.

Farrington C, Whitaker H, Hocine M . Case series analysis for censored, perturbed, or curtailed post-event exposures. Biostatistics. 2008; 10(1):3-16. DOI: 10.1093/biostatistics/kxn013. View

18.

Weldeselassie Y, Whitaker H, Farrington C . Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice. Epidemiol Infect. 2011; 139(12):1805-17. DOI: 10.1017/S0950268811001531. View

19.

Beck C, McKenzie B, Hashim A, Harris R, Nguyen-Van-Tam J . Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis. 2012; 206(8):1250-9. DOI: 10.1093/infdis/jis487. View

20.

Crockett F, Mal H, Amazzough K, Stern M, Rivaud E, Cerf C . [H1N1 (2009) influenza A infection in transplant recipient patients: a comparative study versus non-transplanted patients]. Rev Pneumol Clin. 2011; 67(4):199-208. PMC: 7126570. DOI: 10.1016/j.pneumo.2011.06.004. View